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This study looked at the effect of an external magnet on the biodistribution of magnetoliposomes intravenously
administrated in mice (8 mg iron/kg) with and without induced acute inflammation. Our results showed that due
to enhanced vascular permeability, magnetoliposomes accumulated at the site of inflammation in the absence of
an external magnetic field, but the amount of iron present increased under the effect of a magnet located at the
inflammation zone. This increase was dependent on the time (20 or 60 min) of exposure of the external magnetic
field. It was also observed that the presence of the magnet was associated with lower amounts of iron in the liver,
spleen, and plasma than was found in mice in which a magnet had not been applied. The results of this study
confirm that it is possible to target drugs encapsulated in magnetic particles by means of an external magnet.
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The use of materials in nanoscale provides unparallel
freedom to modify fundamental properties such as solu-
bility, diffusivity, blood circulation half-life, drug release
characteristic, and immunogenicity. In the last two dec-
ades, nanoparticles have attracted widespread attention
due to the rapidly increasing number and variety of their
applications in the biomedical sciences, including im-
aging and therapy [1,2]. Indeed, they possess unique
nanoscale size-dependent physical and chemical proper-
ties that can be controlled in a manner that is not
possible with bulk materials [3]. There are several nano-
particle platforms: liposomes, polymeric conjugates,
polymeric nanoparticles, micelles, nanoshells, dendri-
mers, engineered viral nanoparticles, albumin-based
nanoparticles, polysaccharide-based nanoparticles, cer-
amic nanoparticles, and magnetic nanoparticles.
Among the aforementioned particles, iron oxide-based
magnetic nanoparticles (MNs) have been developed and
represent promising new systems in biomedical sciences,
especially in therapy and imaging [4]. Medical applications* Correspondence: joanestelrich@ub.edu
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reproduction in any medium, provided the origof MNs require that such nanoparticles possess superpara-
magnetic properties at room temperature. This property is
displayed in small subdomain particles (of the order of
tens of nanometers or less; 10 to 15 nm for magnetite).
Superparamagnetic particles have fast relaxation times
and, consequently, show neither remanence nor coercivity.
Thus, these nanoparticles are nonmagnetic in the absence
of an external magnetic field, but they do develop a mean
magnetic moment in an external magnetic field [5].
Therapeutic application of MNs is when they are used
for the site-specific delivery of therapeutic payloads. The
goal of any drug delivery system is to ensure that the
drugs are administered into the body correctly and reach
the target area. Targeting a drug delivery system can be
divided into two general categories: passive and active.
Although both approaches are used, the technical
demands of the two are considerably different. Passive
targeting exploits the natural distribution pattern, i.e.,
the tendency of unmodified particles to accumulate in
certain tissues, which occurs because nanoparticles are
quickly removed from circulation by the cells of the
mononuclear phagocyte system (MPS), in particular, the
resident macrophages of the liver (Kupfer cells), spleen,
lung, and bone marrow [6]. Hence, this strategy serves
to target diseases that affect the MPS. Active targeting
involves modifying the basic structure of nanoparticles
by attaching a homing device to the carrier. Examples ofThis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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such as antibodies - which allow it to complex with the
cell that contains the receptor for the interaction - and
the incorporation of molecules that make the particles
susceptible to pH or temperature changes [7].
MNs share the main advantages of both types of tar-
geting; as with passive targeting, modification of the
nanoparticle surface is not necessary, and like active tar-
geting, they can be directed to the area of interest. This
is due to the fact that MNs respond strongly to time-
modulated magnetic fields, and in turn, magnetic fields
can penetrate human tissues without impediment. Thus,
MNs can be used as a tool for targeting drugs, such as
anticancer or radionuclide atoms, which could be co-
encapsulated within the magnetic nanoparticles and then
carried within the nanoparticle structure under the influ-
ence of an external magnetic field to a targeted area in
the human body. As with MNs, magnetoliposomes
(MLs) formed by encapsulating iron oxide nanoparticles
within liposomes have the advantage of being nontoxic
and biocompatible and displaying magnetophoretic mo-
bility [8,9]. Magnetoliposomes play an important role in
the wide variety of MNs, which are routinely used as
magnetic resonance imaging contrast agents [10,11] and
for controlled drug release [12].
In this paper, we assess the effect of a magnetic field,
generated outside the body, on the biodistribution of mag-
netoliposomes after intravenous administration in mice to
which an inflammatory focus on their back has been
induced. Cancer and inflammation are related by epidemi-
ology, histopathology, and inflammatory profiles [13]. For
this reason, the development of an experimental model to
study in vivo whether the drug correctly reaches and
concentrates at the target site is of great interest. The dis-
tribution of MNs within different organs and timescales
(20 and 60 min) was examined by determining the
amounts of the iron accumulated in the tissues.Methods
Materials
Soybean phosphatidylcholine (PC), a zwitterionic phospho-
lipid (Lipoid S-100), was donated by Lipoid (Ludwigs-
hafen, Germany). Nanoparticles of magnetite stabilized
with anionic coating (EMG 707) were purchased from
FerroTec (Bedford, NH, USA). The particles had a nom-
inal diameter of 10 nm, which was determined by trans-
mission electron microscopy (TEM); a stock solution has
a coefficient of viscosity of less than 5 mPas at 27°C
and a magnetite volume content of 1.8%. Neodymium-
iron-boron (Nd2Fe12B) magnet discs (N35D2510,
25× 10 mm, of 600 mT by side) were obtained from
Halde GAC (Barcelona, Spain). Reagents were of analyt-
ical grade.Preparation and characterization of magnetoliposomes
Magnetoliposomes were obtained using a modified ver-
sion of the phase-reverse method followed by extrusion
at room temperature into a Liposofast device (Avestin,
Inc., Ottawa, Canada) through two polycarbonate mem-
brane filters of 0.2-μm pore size, a minimum of nine
times both ways [14]. Ferrofluid was diluted with 0.16 M
NaCl until an iron concentration of 1.12 mg mL−1 was
achieved, and with this aqueous suspension, the
phospholipid layers were hydrated. Ferrofluid particles
no longer entrapped were removed by size exclusion
chromatography on Sepharose 4B (GE Healthcare, Chal-
font Saint Giles, UK). A total of 250 μL of magnetolipo-
somes was applied to a 1 × 30-cm column saturated with
lipids before sample elution with 0.16 M NaCl. Magne-
toliposomes were then separated from empty liposomes
by means of a MACS separation column (Miltenyi Bio-
tech, Bergisch Gladbach, Germany). The morphology of
magnetoliposomes was observed by TEM using a JEOL
1010 microscope (JEOL Ltd., Akishima, Tokyo, Japan)
operating at 80,000 V. A drop of the aqueous dispersion
of magnetoliposomes was placed onto a 400-mesh cop-
per grid coated with a carbon film with a Formvar mem-
brane and then allowed to air dry before being inserted
into the microscope. Images were recorded with a Mega-
view III camera (Arecont Vision, Glendale, CA, USA),
and the acquisition was accomplished using Soft-
Imaging software (SIS, Münster, Germany). The iron
content of the magnetic particles was determined on the
basis of the ferrous ion using o-phenanthroline [15]. The
phospholipid content was determined by the Stewart-
Marshall method [16]. The hydrodynamic diameter of
magnetoliposomes was determined by dynamic light
scattering (DLS) at 90° with the Zetasizer Nano (Mal-
vern Instruments Ltd., Malvern, Worcestershire, UK) at
a temperature of 25°C. The particle size distribution was
designated by the polydispersity index (PI), which ranged
from 0.0 for an entirely monodisperse sample to 1.0 for
a polydisperse sample. The ζ-potential measurements of
magnetoliposomes were performed at 25°C using the
Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern,
Worcestershire, UK).Animal and biological methods
Experiments were performed on 8-week-old female CD-
1 mice with a body weight of 28 to 32 g (Harlam Ibérica,
Sant Feliu de Codines, Barcelona, Spain). Animals were
provided with food and tap water ad libitum and
allowed a 1-week acclimation period after arrival to the
animal facilities of the Faculty of Pharmacy. The animals
were then allowed an additional week to adjust to
restraining conditions. The study was conducted under a
protocol approved by the Animal Experimentation
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Mice were randomly divided into four groups (be-
tween seven and eight animals per group): (a) healthy
control saline (C): animals with back air pouch receiving
saline i.v. (0.1 mL/10 g body weight); (b) inflammation
control group (I): animals with carrageenan-induced in-
flammation in the air pouch receiving saline i.v.; (c) in-
flammation magnetoliposomes (IN): animals with
carrageenan-induced inflammation receiving magnetoli-
posomes i.v.; and (d) inflammation magnetoliposomes
with magnet (INM): as in the previous group (IN), but
under the effect of a magnet located just above the in-
flammatory pouch for 20 or 60 min. All injections and
painful procedures were performed under isoflurane
(Laboratorios Esteve, Barcelona, Spain) anesthesia (4%
induction and 3% maintenance).
The method used to induce acute inflammation was
similar to that described by Romano et al. [17]. Briefly,
sterile air pouches were produced by injecting 5 mL of air
subcutaneously (s.c.) through a disposable disc filter (EPSW
Inc., Ivyland, PA, USA; 2 μm) into the back of the mouse
(day 0); the pouches were injected again with 3 mL of air
on day 3. On day 4, the pouches from the mice in group C
received 1-mL saline (B Braum Medical, Barcelona, Spain),Figure 1 Experimental procedure performed to establish the effect oand the pouches from the mice in groups I, IN, and INM
received 1-mL carrageenan lambda 1.2% s.c. (Sigma-
Aldrich, St. Louis, MO, USA).
On day 5, 24 h after the phlogogen injection, the ani-
mals received 0.1 mL/30 g saline (group C) or magneto-
liposomes (8 mg of iron/kg body weight) in saline
(groups I, IN, and INM) i.v. through a jugular vein and
were placed in restrained Plexiglas cages with air holes.
Some mice did not have disc magnets on their backs
(groups C, I, and IN) while some did for 20 or 60 min.
Before i.v. administration, a small incision was made in
the neck to one side of the midline. A 30-G needle was
used for the injection (Becton Dickinson D Ultra-Fine
U-100 insulin Syringe, USA) and was inserted into the
vein through the pectoral muscle at an approximate
angle of 10°, pointing toward the head. The muscle acts
as a seal when the needle is withdrawn. To close the skin
incision, one or two sterile silk suture 4/0 points were
applied (Laboratorios Aragó, Barcelona, Spain).
After 20 or 60 min of i.v. dosing, mice were anesthe-
tized, thoracotomy was performed, and the blood was
harvested by cardiac puncture using a 27-G Becton
Dickinson tuberculin syringe with needle. Plasma was
obtained by centrifugation (10,000 × g for 5 min) (Her-
aeus Biofuge Pico, Hanau, Germany). When the heartf external magnet on biodistribution of MLs.
Figure 2 Size distribution expressed as z-diameter of
magnetoliposomes after purification by size exclusion
chromatography. Inset: TEM micrograph of non-stained
magnetoliposomes.
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ultra analytics system, ELGA, Veolia Water, Barcelona,
Spain) was injected into the pouch. The pouch was gen-
tly massaged, and the mouse was placed in the supine
position on the top of a plastic funnel. An incision was
made in the pouch, and the exudates were collected in
5-mL polyethylene tubes and weighed. The liver and
spleen were harvested and dried by placing the samples
in a laboratory heater at 60°C for 24 h. Figure 1 shows a
schematic of the experimental procedure carried out.
Analytical determinations
To control inflammation, the volume (in milliliters) and
protein content (in milligrams per milliliter) of the exud-
ate were determined. The volume was determined by
weighing the exudates, and the protein content was
measured using the bicinchoninic acid assay [18]. The
iron content in the plasma, exudates (pouch), and
organs was analyzed by inductively coupled plasma op-
tical emission spectrometry (Perkin-Elmer Optima
3200RL, Massachusetts, USA) after acid digestion of the
organic material in closed systems. Microwave digestion
(210°C, 1 h) was performed on organs, and digestion for
plasma and exudates was carried out in Teflon vessels
(90°C, 24 h).
The results are expressed as micrograms of iron per
gram of dried tissue. The statistical significance of iron
concentrations was analyzed using ANOVA followed by
the post hoc Fisher’s LSD test. Statistical significance
was accepted at the 5% level (P ≤ 0.05).
The presence of magnetoliposomes in the exudate was
observed by TEM. To obtain the magnetoliposomes
from the exudate, the exudate was eluted through the
MACS separation column, and a drop of the aqueous
dispersion after air drying was observed into the micro-
scope as previously explained.
Results
The obtained magnetoliposomes contain 0.135 ± 0.005 g
Fe3+ per mmol of phospholipid. The size of the magne-
toliposomes determined by DLS ranged from 150 to
190 nm (Figure 2) with a single peak centered at
183 nm. This is consistent with our earlier results [12].
As can be observed, the magnetoliposomes are arranged
in a monomodal distribution (PI < 0.2). The MLs cap-
tured within the phospholipid bilayer appear as clusters
of ferrofluid particles (inset of Figure 2). At pH 7.4, a
ζ-potential value of −23.5 ± 2.4 mV was obtained. This
negative charge is conferred by the external phospho-
lipid monolayer. Although PC is electrically neutral, the
distribution of charges in its polar head region is asym-
metrical. The negative ζ-potential of the liposomes is
caused by the orientation of PC molecules in the lipo-
some membrane.The tissue distribution of iron oxide entrapped in
magnetoliposomes and injected intravenously into mice
from the four groups was studied 20 and/or 60 min after
the injection. The presence of magnetoliposomes in the
exudate is due to the hyperpermeability of the microvas-
culature in the inflammatory process. Therefore, in
order to evaluate the biodistribution of magnetolipo-
somes, only those mice that demonstrated a protein con-
centration in exudates between 3.5 and 8.5 mg mL−1 as
well as a similar volume of exudates for the animals
induced with inflammation (2.6 ± 0.2 mL) were consid-
ered Values from 0.2 to 1.0 mg mL−1 are characteristic
of an absence of inflammation.
Tables 1 and 2 summarize the results obtained for vol-
ume and protein content in the pouch, as well as for the
iron content in the exudates, plasma, liver, and spleen 20
and 60 min after the injection of magnetoliposomes.
The amount of iron determined in biological liquids and
organs was higher after 60 min than after 20 min. The
absence of a magnet resulted in a preferential accumula-
tion of magnetoliposomes in the spleen and liver, con-
sistent with the uptake of such particles by the
mononuclear phagocyte system. The presence of the
magnet (INM) resulted in a decrease in the iron present
in the liver (P < 0.05) in comparison with group IN (a re-
duction of 23% after 20 min of the injection and of 25%
after 60 min). In the plasma, the external magnet pro-
voked a significant reduction of 30% and 31% for 20 and
60 min, respectively (P < 0.05). In the spleen, the reduc-
tion was less pronounced (13% and 16% for 20 and
60 min, respectively). Such reductions can be explained
by the increase in iron content in the exudates. Table 1
shows how the levels of iron in the inflammatory focus
Table 1 Volume and protein content of the exudates and iron concentration in exudates, plasma, liver, and spleen
Groups Pouch Iron concentration (μg g−1)
Volume (mL) Protein (mg mL−1) Exudates Plasma Liver Spleen
C 1.96 ± 0.24 0.61 ± 0.37 0.04 ± 0.04 4.04 ± 1.02 621 ± 310 665 ± 180
I 2.38 ± 0.33a 5.69 ± 2.01a 0.26 ± 0.13a 4.01 ± 1.27 712 ± 224 836 ± 278
IN 2.74 ± 0.24a 5.23 ± 1.43a 0.33 ± 0.11a 4.12 ± 1.07 873 ± 99a 1,446 ± 390a,b
INM 2.57 ± 0.05a 4.63 ± 0.21a 0.56 ± 0.12a,b,c 2.89 ± 0.42 674 ± 64c 1,264 ± 35a,b
The values are expressed as mean ± SD and were obtained 20 min after the injection of magnetoliposomes. a,b,c Significant differences (P< 0.05) with groups C, I,
and IN, respectively (n≥ 5).
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60 min) after the injection.
As we have considered that the biodistribution of the
MNs was in equilibrium with the distribution of iron, an
increase in iron concentration in exudates in the IM and
IMN groups was attributed to the presence of MNs in
the target. To confirm this hypothesis, we determined
whether MNs were present in exudates by visualizing
them using TEM.
To determine whether magnetoliposomes were
present in exudates, we separated them from the liquid
using a magnetic separator. They can also be separated
by centrifugation due to the high density of such lipo-
somes, caused by iron loading. However, the magnetic
separator allows us to concentrate on them. After this,
they were visualized using TEM. Figure 3 shows the
presence of magnetoliposomes in the exudates. The ma-
jority of the magnetoliposomes maintained their original
form and size.
Discussion
The aim of this study was to determine whether magne-
toliposomes could be directed in vivo to target sites
under the effect of an external magnet, consequently
avoiding modification of the liposomes. There are
reports in the literature that this external stimulus ac-
tively locates and accumulates the drug at the targeted
region [19]. It is known that liposomes (and therefore
magnetoliposomes) can be directed through the functio-
nalization of the external layer. For instance, liposomes
with the RGD peptide exposed on their surface are able
to bind vascular endothelial cells at inflammation sitesTable 2 Volume and protein content of the exudates and iron
Groups Pouch
Volume (mL) Protein (mg mL−1) Exudat
C 2.14 ± 0.02 0.63 ± 0.20 0.19 ± 0.1
I 2.80 ± 0.23a 5.90 ± 2.53a 0.50 ± 0.1
IN 2.85 ± 0.13a 5.20 ± 1.60a 0.64 ± 0.2
INM 2.77 ± 0.18a 4.95 ± 1.01a 1.92 ± 1.4
Values are expressed as mean± SD and were obtained 60 min after the injection of
IN, respectively (n≥ 5).[20]. The inflammatory reaction is one of the body’s
defense mechanisms. When damage occurs, blood flow
is firstly increased at the point of injury, and blood ves-
sels widen to allow oxygen, clotting agents, and white
blood cells to penetrate the damaged tissues. Since the
size of white blood cells is ranging from 7 to 20 μm, any
nanoparticles can easily pass through the vessels and lo-
cate in the inflammation zone. To achieve an inflamma-
tion zone, we used mice with induced air pouches.
Among many animal models of inflammation (sponge
implant, paw edema, peritoneal, pleurisy, and air pouch),
the air pouch model has the advantage of not involving
internal organs, which can be damaged or perforated
during sampling [21]. On the other hand, we have used
a strong magnet (600 mT of surface strength of mag-
netic field) to assure that the magnetic field lines are
penetrating the body deeply, that is, the technique is not
only applicable for tissues located at the body’s surface.
However, the strength of the magnetic field falls off very
quickly as the surface of the magnet is moved away from
the target area. Besides the material of the magnet, the
mass of the magnet has an important effect on its overall
strength. The larger the mass of the magnet, the stron-
ger and more effective (more uniform magnetic field) it
will be. For this reason, we have used two magnets above
one another (see Figure 1).
Conclusions
By using this approach (model of inflammation and
strong magnet) and excluding animals with levels of iron
and volumes of exudates out of the range of average
values observed during inflammation, we secured a fairlyconcentration in exudates, plasma, liver, and spleen
Iron concentration (μg g−1)
es Plasma Liver Spleen
2 4.45 ± 0.33 547 ± 91 914 ± 403
0 4.12 ± 0.68 605 ± 114 1,039 ± 227
7 4.25 ± 1.43 1,174 ± 134a,b,c 1,611 ± 378a,b
4a,b,c 2.94 ± 0.38a,b,c 880 ± 97a,b,c 1,354 ± 260a,b
magnetoliposomes. a,b,c Significant differences (P< 0.05) with groups C, I, and
Figure 3 TEM micrograph of non-stained magnetoliposomes
found in exudates of a mouse (IMN). The magnetoliposomes
were found 20 min after intravenously injecting the particles. Inset:
an enlarged image of a magnetoliposome.
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an external magnetic field on the distribution of magne-
toliposomes after injecting them intravenously. We
observed the accumulation of magnetoliposomes at the
site of inflammation (exudates) and, at the same time,
the removal from the blood compartment, and the de-
crease in the liver and spleen. As shown in Tables 1 and
2, the increase in iron levels in exudates depends on the
time of exposure of the external magnetic field; when
comparing IN and INM groups, an increase of 70% and
200% was observed for 20 and 60 min, respectively.
After this point, the magnetic field efficiently retains
MNs. This method can also be used to enhance the ac-
cumulation of a certain drug (i.e., corticosteroid, hyalur-
onic acid) after an intra-articular injection, thus avoiding
the need of repeated injections due to rapid clearance
from the joint [22]. The fact that magnetoliposomes re-
main intact in the exudates 20 min after the injection is
not surprising since with a diameter close to 12 nm, the
magnetite particles are too large to passively cross the
phospholipid bilayer. Only after the action of destabiliz-
ing agents, such as opsonins and cells of the mono-
nuclear phagocyte system, the iron content may leave
the interior of the magnetoliposomes. In conclusion, this
study has demonstrated the efficacy of the magnet
method. We have shown that when loaded with a suit-
able therapeutic agent, an anti-inflammatory in this case,
magnetoliposomes, under the effect of a magnetic field
can be used to treat the inflammatory process or other
pathologies, and in doing so, it can reduce the drug dose
administered and increase the efficacy of the treatment.
Moreover, the observed reduction in the levels in the
blood could prevent side effects.Competing interests
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